Research location
Barrie
Canada
Advertisement
Research activity in Barrie
CanadaCureCurrent currently publishes aggregate city-level research activity for this location: 20 trials and 20 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Barrie
20 linked trials · page 1 of 1Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04 · 1 site observation
RECRUITING
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · 2023-02-08 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734 · 2021-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165 · 2019-07-24 · 1 site observation
COMPLETED
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)NCT03767543 · 2019-03-11 · 1 site observation
COMPLETED
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisNCT02647762 · 2017-10-30 · 1 site observation
TERMINATED
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)NCT03260868 · 2017-09-19 · 1 site observation
TERMINATED
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusNCT03216226 · 2017-06-28 · 1 site observation
COMPLETED
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic SyndromeNCT03081598 · 2017-05-29 · 1 site observation
TERMINATED
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisNCT03025308 · 2017-02-28 · 1 site observation
COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminNCT02926950 · 2016-11-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid ArthritisNCT02504671 · 2015-07-23 · 1 site observation
COMPLETED
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation
COMPLETED
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to MethotrexateNCT01500278 · 2011-12-01 · 1 site observation
COMPLETED
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)NCT00517790 · 2007-08-01 · 1 site observation
COMPLETED
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsNCT00332917 · 2007-02-01 · 1 site observation
COMPLETED
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)NCT00404547 · 2006-11-01 · 1 site observation
COMPLETED
SLV308 for Treatment of Patients With Early Parkinson's DiseaseNCT00269516 · 2006-06-01 · 1 site observation
COMPLETED
Tamoxifen in Treating Women With High-Risk Breast CancerNCT00002542 · 1993-07-20 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.